Table 6.

Combinations of MAbs/BsAbs being tested in Phase I and II clinical trials.

First Specificity	Combined with Antibodies Against	Category of Combination	Diseases	References
PD-1 or PD-L1	TIGIT	2 ICI	Solid tumors and hematological malignancies	[43] [154] [155] [160] [166] [177] [183] [193]
	TIM3
	LAG3
	NKG2A
	CD73
	PVRIG
	CD47
	CD137	ICI + immune stimulator
	OX40
	CD27
	GITR
	EGFR	ICI + anti-tumor MAb
	HER2
	CD20
	CD22
	CCR4
	FGFR3
	CD19 × CD3 ± CTLA4	ICI + TE BsAb
	CD20 × CD3
	gPA × CD3
	VEGF × ANG2	ICI + anti-angiogenic BsAb
	C5aR	ICI + anti-complement receptor
	TGF-β RII	Miscellaneous
	RANKL ± CTLA4
CTLA4	LAG3	2 ICI	Melanoma	[152]
	OX40	ICI + immune stimulator	Solid tumors	[169]
	EGFR	ICI + anti-tumor MAb	HNSCC	[177]
OX40	CTLA-4 ± PD-1	2 ICI + immune stimulator	Solid tumors	[166]
	CD137	2 immune stimulator	Solid tumors
	TLR4 ot TLR9
	CD20	immune stimulator + anti-tumor MAb	DLBCL
CD27	GPNMB (ADC)	immune stimulator and ADC	Melanoma	[166]
CD137	CCR4	immune stimulator and anti-tumor MAb	Advanced solid tumors	[166,199]
	CD20 ± PD-L1		DLBCL
	EGFR		CRC
	HER2 (Mab or ADC)		Breast cancer
	OX40+PD-L1	2 immune stimulators and 1 ICI antibody	Solid tumors
CD47	EGFR	ICI + anti-tumor MAb	Colorectal	[162]
	CD20		B-NHL
NKG2A	EGFR	ICI + anti-tumor MAb	Squamous cell carcinoma of head and neck	[157]
CD73	EGFR	ICI + anti-tumor MAb	Solid tumors	[160]
LAG3	PD-1 + TIM3	3 ICI antibodies	Solid + Lymphoma	[152]
	PD-1 + CTLA4 ± CD38	3 ICI MAbs + anti-tumor MAb	Advance tunors
	PD-1 + CD137	2 ICI MAbs + 1 immune stimulator	Glioblastoma
GITR	PD-1 ± CTLA4	2 ICI MAbs + 1 immune stimulator	Solid tumors	[166]